Online Inquiry
Recombinant Human Fibroblast growth factor receptor 1 (FGFR1), partial
SPP-01863
| Size | Price |
| 1 mg | Online Inquiry |
| 100 μg | Online Inquiry |
| 20 μg | Online Inquiry |
| Target Information | |
|---|---|
| Species | Homo sapiens |
| Target Name | FGF Receptor |
| UniProt No. | P11362 |
| Subcellular Location | Cell membrane, Single-pass type I membrane protein, Nucleus, Cytoplasm, cytosol, Cytoplasmic vesicle |
| Tissue Specificity | Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells. |
| Gene Abbr. | FGFR1 |
| Full Name | fibroblast growth factor receptor 1 |
| Alias | BFGFR, CD331, CEK, ECCL, FGFBR |
| Introduction | Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain. Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues. Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling. The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ.FGFR2 has several splicing isoforms, with ligand specificity largely determined by alternative splicing of exons 8 (IIIb) and 9 (IIIc). Alternative splicing is cell type specific, resulting in isoforms showing various tissue distribution and biological activities. Research studies have shown that mutations in the corresponding FGFR2 gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, Pfeiffer Syndrome, Apert Syndrome, and Jackson-Weiss Syndrome. Investigators have also observed mutations and altered expression of FGFR2 in cases of gastric, endometrial, and breast cancer. |
| Product Details | |
|---|---|
| Product Type | Recombinant Protein |
| Buffer before Lyophilization | If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Note: If you have any special requirement for the glycerol content, please remark when you place the order. |
| Storage & Handling | |
|---|---|
| Storage Temp. | Store at -20 °C upon receipt unless otherwise instructed. |
| Handling | Aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.